In this issue:
Neoantigen cancer vaccine promising for RCC
Belzutifan has durable efficacy in VHL disease-associated RCC
Belzutifan bests everolimus for quality-of-life outcomes in RCC
Survival benefit to salvage TICE in higher-risk germ cell tumours
Time toxicity in end-stage mCRPC
Quadruple antiemetic therapy efficacious in patients with germ cell tumours
Limited activity of DFF332 in advanced RCC
Upfront nephrectomy may be optimal for synchronous RCC
SBRT is an effective option for inoperable RCC
CRiSS accurately identifies patients with ILNM from penile SCC
Please login below to download this issue (PDF)